is semaglutide fda approved for obesity Wegovy® – A New Treatment FDA approves obesity drug that

GLP-1 refers to prescription medication your clinician may use as part of a weight management plan

For more information, call 1-800-545-5979

Microbial transglutaminase: A new potential player in celiac disease

This work provides the first systematic assessment of subcutaneous vs

Thyroid tumor warning: All semaglutide medications also carry an FDA boxed warning for a potential risk of thyroid C-cell tumors based on animal studies, although it is unknown whether this risk applies to humans

Findings: Left complete cleft lip and palate with associated cleft nasal deformity Complications: None Immediate Postop Condition: Stable to PACU Disposition: PACU, admit Estimated Blood Loss: 5 cc IV Fluids Given: 50 cc Urine Output: Not recorded Drains/Implants: None Specimens: None Antibiotics: Ancef DVT Prophylaxis: Not indicated for age Description of Procedure: The patient was taken to the operating room and placed supine on the operating table